Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of 177Lu-PSMA therapy after SBRT versus observation in PSMA-positive oligometastatic prostate cancer
MOH_2023-10-19_012771Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Sep 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) comparing Observation group with Pluvicto treatment group (2 arms). Started Sep 2023; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2023-10-19_012771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-10-19_012771.